Tag Archives: GLP-1 receptor agonists

The potential link between GLP‑1 therapies and depression has sparked growing interest among clinicians and researchers. If you’ve ever wondered whether glucagon‑like peptide‑1 (GLP‑1) receptor agonists could positively influence mood, you’re not alone. Early research suggests these medications may ease depressive symptoms by dampening inflammation and influencing brain signaling, though …

GLP‑1 receptor agonists have changed the way we treat type 2 diabetes and obesity, offering powerful glucose-lowering effects and sustained weight loss. But as more patients stay on these medications for years—not just months—questions around GLP‑1 long‑term safety have become essential to address. From gastrointestinal discomfort to gallbladder risks and …

The GLP‑1 mechanism of action is more than a tool for lowering glucose—it’s a central player in a complex system influencing body weight, cardiovascular outcomes, liver health, and possibly even brain function. As GLP‑1 receptor agonists become more widely prescribed, understanding how this pathway works helps clinicians better tailor treatments …

Early research suggests GLP‑1 drugs may reduce alcohol intake by dampening reward signaling and hedonic hunger, sparking interest among diabetes clinicians about the potential of GLP-1 alcohol use reduction. While findings so far are promising, understanding the nuances of the evidence is essential when talking with patients. This article explores …

GLP‑1 receptor agonists have transformed the way we manage type 2 diabetes and obesity—but could they also play a role in sleep apnea treatment? The intersection of GLP-1 sleep apnea benefits is gaining attention, with new evidence suggesting these therapies may offer more than just weight loss. With diabetes and …

As the landscape of diabetes care evolves, one question continues to surface: are we focusing too much on glucose and not enough on the bigger cardiometabolic picture? In recent years, glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs) have moved from glucose-focused agents to powerful tools in cardiovascular and metabolic risk reduction. …

  As the burden of diabetic kidney disease (DKD) continues to grow, so does the urgency for early, evidence-based interventions. The concept of kidney protection diabetes is shifting—clinicians are now encouraged to initiate therapy before substantial kidney function loss occurs. Two major drug classes—SGLT2 inhibitors and GLP‑1 receptor agonists—are leading …

Treating type 2 diabetes is no longer a one-size-fits-all endeavor. As new therapies emerge, clinicians face the ongoing challenge of selecting and sequencing medications in a way that balances efficacy, safety, cost, and patient preference. This comprehensive guide to type 2 diabetes drug sequencing outlines practical strategies for initiating, intensifying, …

Clinicians and care teams are increasingly focused on GLP‑1 receptor agonists, but SGLT2 inhibitors and metformin in diabetes management remain foundational in achieving comprehensive, evidence‑based outcomes. While GLP‑1 therapies generate headlines for weight loss and glucose control, 2025 guidelines still strongly emphasize the cardioprotective and renoprotective benefits of SGLT2 inhibitors …

The class of medications known as GLP-1 receptor agonists — commonly prescribed for type 2 diabetes and increasingly used for weight loss — may offer more than just metabolic benefits. Growing evidence indicates that GLP-1 drugs could play a role in protecting the brain. Could this mean a dual benefit …